PEN Insider Trading

Insider Ownership Percentage: 5.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $39,988,786.76

Penumbra Insider Trading History Chart

This chart shows the insider buying and selling history at Penumbra by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$18MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Penumbra Share Price & Price History

Current Price: $260.75
Price Change: Price Decrease of -6.381 (-2.39%)
As of 03/13/2025 04:58 PM ET

This chart shows the closing price history over time for PEN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$266.51Closing price on 03/12/25:

SEC Filings (Institutional Ownership Changes) for Penumbra (NYSE:PEN)

88.88% of Penumbra stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PEN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$497Mbought$591MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
Penumbra logo
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Read More on Penumbra

Today's Range

Now: $260.75
Low: $256.54
High: $266.93

50 Day Range

MA: $269.26
Low: $236.12
High: $303.55

52 Week Range

Now: $260.75
Low: $148.00
High: $310.00

Volume

281,756 shs

Average Volume

397,283 shs

Market Capitalization

$10.04 billion

P/E Ratio

766.91

Dividend Yield

N/A

Beta

0.51

Who are the company insiders with the largest holdings of Penumbra?

Penumbra's top insider shareholders include:
  1. Adam Elsesser (CEO)
  2. Arani Bose (Director)
  3. Johanna Roberts (EVP)
  4. Lambert Shiu (CAO)
  5. Maggie Yuen (CFO)
  6. Harpreet Grewal (Director)
  7. Bridget O'rourke (Director)
  8. Surbhi Sarna (Director)
  9. Don W Kassing (Director)
  10. Thomas Wilder (Director)
Learn More about top insider investors at Penumbra.

Who are the major institutional investors of Penumbra?

Penumbra's top institutional shareholders include:
  1. FMR LLC — 15.16%
  2. Vanguard Group Inc. — 9.51%
  3. Champlain Investment Partners LLC — 3.90%
  4. Price T Rowe Associates Inc. MD — 3.30%
  5. William Blair Investment Management LLC — 2.30%
  6. RTW Investments LP — 2.25%
Learn More about top institutional investors of Penumbra stock.

Which institutional investors are selling Penumbra stock?

In the last quarter, PEN stock was sold by these institutional investors:
  1. Price T Rowe Associates Inc. MD
  2. JPMorgan Chase & Co.
  3. Braidwell LP
  4. Man Group plc
  5. William Blair Investment Management LLC
  6. Renaissance Technologies LLC
  7. FMR LLC
  8. Janus Henderson Group PLC
Within the previous year, company insiders that have sold Penumbra company stock include:
  1. Adam Elsesser (CEO)
  2. Arani Bose (Director)
  3. Johanna Roberts (EVP)
  4. Lambert Shiu (CAO)
  5. Maggie Yuen (CFO)
  6. Harpreet Grewal (Director)
  7. Bridget O'rourke (Director)
Learn More investors selling Penumbra stock.

Which institutional investors are buying Penumbra stock?

In the last quarter, PEN stock was bought by institutional investors including:
  1. Norges Bank
  2. T. Rowe Price Investment Management Inc.
  3. Baillie Gifford & Co.
  4. Adage Capital Partners GP L.L.C.
  5. Baird Financial Group Inc.
  6. Allspring Global Investments Holdings LLC
  7. Voya Investment Management LLC
  8. RTW Investments LP